Compare · BHSE vs TECH
BHSE vs TECH
Side-by-side comparison of Bull Horn Holdings Corp. (BHSE) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHSE and TECH operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TECH is the larger of the two at $14.42B, about 153.7x BHSE ($93.8M).
- TECH has hit the wire 6 times in the past 4 weeks while BHSE has been quiet.
- TECH has more recent analyst coverage (22 ratings vs 0 for BHSE).
- Company
- Bull Horn Holdings Corp.
- Bio-Techne Corp
- Price
- $12.50+50.42%
- $54.19+3.79%
- Market cap
- $93.8M
- $14.42B
- 1M return
- -
- +2.81%
- 1Y return
- -
- +7.82%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 22
Bull Horn Holdings Corp.
Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest BHSE
- SEC Form SC 13G filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- SEC Form 424B3 filed by Bull Horn Holdings Corp.
- Bull Horn Holdings Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- Cogley Brian bought $3,350 worth of shares (5,000 units at $0.67), increasing direct ownership by 20% to 30,000 units (SEC Form 4)
- New insider Cogley Brian claimed ownership of 30,000 shares (SEC Form 3)
- Desilva Tara bought $1,305 worth of shares (2,266 units at $0.58), increasing direct ownership by 8% to 32,266 units (SEC Form 4)
- Yerace Daniel Alexander bought $7,486 worth of shares (10,850 units at $0.69), increasing direct ownership by 1% to 1,071,455 units (SEC Form 4)
- Salkind Gene bought $8,004 worth of shares (11,600 units at $0.69), increasing direct ownership by 4% to 284,056 units (SEC Form 4)
- Mehalick David bought $16,747 worth of shares (25,054 units at $0.67), increasing direct ownership by 0.91% to 2,782,615 units (SEC Form 4)
Latest TECH
- Chief Executive Officer Kelderman Kim converted options into 11,344 shares and covered exercise/tax liability with 1,363 shares, increasing direct ownership by 19% to 63,058 units (SEC Form 4)
- CFO Hippel James covered exercise/tax liability with 56,097 shares and converted options into 62,000 shares, increasing direct ownership by 4% to 148,625 units (SEC Form 4)
- SEC Form 4 filed by Kelderman Kim
- Bio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
- Bio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
- SEC Form 4 filed by Bohnen Shane
- Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp
- Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
- SEC Form 4 filed by President - Diag & Spatial Bi Crouse Steven C.
- New insider Crouse Steven C. claimed ownership of 5,894 shares (SEC Form 3)